November 23, 2016 5:10pm

 

… Even one day away from this market will soothe the soul …

 

We’re headed into Thanksgiving and traders don’t want to have risky positions going into a day off, a market half-day, and a weekend

 

… As Juno Therapeutics (JUNO) shares plunged 24.4% after announcing deaths that compromised its experimental leukemia treatment/drug <JCAR015> trial

 

 

I answer one question; in which company should investors put, keep and commit their money!

Pre-open indication’s tally:  5 hits (AGTC, KOOL, IMUC, FATE and OPXA) and 0 miss

 

Lose an advantage or be a subscriber!  Today’s results have implications to Friday's sector activity.  

 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 


 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

U.S. stocks closed mixed on Wednesday as investors digested a number of economic data, including minutes from the Federal Reserve's November meeting.

The NASDAQ closed DOWN -5.67 or -0.11% to 5,380.68 and the DOW closed UP +59.31 or +0.31% to 19,083.18.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 8/31 and 4 flats;                       
  • The mid-day stayed negative with an A/DL of 16/26 and 1 flat;
  • The closing bell was negative with A/DL of 20/21 and 2 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.

  • From this morning’s investor’s letter, “A good day to be a buyer … Little volume, a thinning field, speculative sentiment, depreciating indexes and ETFs  and a sector with focus elsewhere …  Re stocks, I’d be looking to play “pick-up-stocks”

 

The iShares Russell 2000 (IWM) indicated a negative pre- open of -0.41% and closed UP +0.63% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open negative of -1.78% and closed UP +0.88%.

 

  • The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded higher, near 12.6.

Markets will be shut on Thursday and then will close early on Friday.

 

Many traders and other market participants will be out for the holiday, which could mean a quieter market, although the lighter volume could also leave it susceptible to bigger swings if unexpected headlines occur.

 

 

At the close …

Gainers included

  • Spark Therapeutics (ONCE +$1.93 after Tuesday’s -$2.38),
  • bluebird bio (BLUE +$1.55 after Tuesday -$1.55),
  • Regenxbio (RGNX +$1.50),
  • Intrexon (XON +$0.97) and
  • Fate Therapeutics (FATE +$0.35 after Tuesday’s+$0.28) contributed the most gains;

The biggest losers of the session were

  • Juno Therapeutics (JUNO -$7.315 after Tuesday’s -$1.56),
  • Kite Pharma (KITE -$0.79), Cellectis SA (CLLS -$0.53),
  • Asterias Biotherapeutics (NYSEMKT: AST -$0.35) and
  • ImmunoCellular (NYSEMKT: IMUC -$0.33)

 

 

The downside trend reflects a pricing trend range of:

  • Wednesday’s decliners ranged from -2.17% <MESO> to -24.48% <JUNO> in 21 equities;
  • Tuesday’s decliners ranged from – 0.16% <CAPR> to -28.57% <OPXA> in 26 equities;
  • Monday’s decliners ranged from -0.58% <XON> to -15.49% <ADVM> in 15 equities;
  • Friday’s decliners ranged from -0.31% <ONVO>to -12.34% <NWBO>in 17 equities
  • Thursday’s decliners ranged from -0.78% <JUNO> to-21.28% <STEM> in 15 equities;
  • Last Wednesday’s decliners ranged from -0.42% <STML> to -14.93% <IMUC> in 26 equities;

 

The upside shows a pricing trend range of:

  • Wednesday’s gainers ranged from + 0.01% <FCSC> to +11.90% <FATE> in 20 equities;
  • Tuesday’s gainers ranged from +0.26% <VTGN> to +10.53% <FATE> in 14 equities;
  • Monday’s gainers ranged from +0.14% <QURE> to +4831.3% (IMUC – after a reverse split> in 26 equities;
  • Friday’s gainers ranged from +0.21% <MESO> to +21.82% <OPXA> in 24 equities;
  • Thursday’s gainers ranged from +0.14% <IMUC> to +12.50% in 28 equities;
  • Last Wednesday’s gainers ranged from +0.46% <OSIR> to +31.78% <STEM> to in 13 equities;

 

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers.

  • Wednesday’s 20 gainers followed Tuesday’s 14 gainers after Monday’s 26 gainers compared to Friday’s 24 following Thursday’s 28 following last Wednesday’s 13 post …

 

  • Wednesday’s 21 decliners followed Tuesday’s 26 decliners after Monday’s 15 after Friday’s 17 as compared to Thursday’s 15 following last Wednesday’s 26 ...

 

 

Pre-open indication’s tally:  5 hits (AGTC, KOOL, IMUC, FATE and OPXA) and 0 miss

  • Applied Genetic Technologies (AGTC) closed UP +$0.20 – hit;
  • Cesca Therapeutics (KOOL) closed DOWN -$0.25 – hit;
  • ImmunoCellular (NYSEMKT: IMUC) closed DOWN -$0.33 – hit;
  • Fate Therapeutics (FATE) closed UP +$0.35 – hit;
  • Opexa (OPXA) closed DOWN -$0.14 – hit;

 

 

Percentage decliners:

  • Juno Therapeutics (JUNO) -24.50%;
  • Opexa (OPXA) -13.62% after Tuesday’s -28.57% after Monday’s +119.4% after Friday’s +21.82% after Thursday’s -6.76% after last Wednesday’s +5.34%;
  • ImmunoCellular (NYSEMKT: IMUC) -10.34%;
  • Northwest Bio (NWBO) -7.96% after Tuesday’s +8.95% after Monday’s +8.06% after Friday’s -12.34%;
  • Cesca Therapeutics (KOOL) -7.79% after Tuesday’s +7.36% after Monday’s -6.85% after Friday’s -5.31% after Thursday’s +7.62%;

 

 

 

 

Percentage advancers:

  • Fate Therapeutics (FATE) +11.90% after Tuesday’s +10.53%;
  • Regenxbio (RGNX) +7.35% after Tuesday’s -5.34%;
  • Vericel (VCEL) +4.26%;
  • Neuralstem (CUR) +3.81% after Tuesday’s -7.11% after Monday’s -4.11%;
  • Spark Therapeutics (ONCE) +3.59%

 

 

Flat:                                                                                                      

  • Adverum (ADVM) at $3.00;
  • Pluristem (PSTI) at $1.51;
  • ReNeuron (RENE.L) at $2.625;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Wednesday traded near 12.6;

·         Tuesday traded near 12.6;

·         Monday traded 12.5;

·         Friday traded near 13.2;

·         Thursday traded near 13.5;

·         Last Wednesday traded near 13.9;

 

                                                                                                             

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.